Use of indwelling, double-pigtail stents for treatment of malignant ureteral obstruction in dogs: 12 cases (2006-2009)

Journal of the American Veterinary Medical Association

Volumn 238, Issue 8, 2011, Pages 1017-1025

  Berent, Allyson C ^a,d   Weisse, Chick ^a,d   Beal, Matthew W ^b   Brown, Dorothy C ^a   Todd, Kimberly ^a   Bagley, Demetrius ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d ANIMAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; CARCINOMA; DOG; DOG DISEASE; FEMALE; MALE; RETROSPECTIVE STUDY; STENT; TREATMENT OUTCOME; URETER OBSTRUCTION; URETER TUMOR;

ANIMALS; CARCINOMA; DOG DISEASES; DOGS; FEMALE; MALE; RETROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME; URETERAL NEOPLASMS; URETERAL OBSTRUCTION;

ANIMALIA; CANIS FAMILIARIS;

EID: 79955621491     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.238.8.1017     Document Type: Article

References (35)

1. Uthappa MC, Cowan NC. Retrograde or antegrade doublepigtail stent placement for malignant ureteric obstruction? Clin Radiol 2005;60:608-612.
2. Zimskind PD, Fetter TR, Willierson JL. Clinical use of longterm indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 1967;97:840-844.
3. Finney RP. Experience with a new double-J ureteral stent. J Urol 1978;120:678.
4. Grasso M, Bagley DH. Flexible cystoscopic placement of ureteral stents before shock wave lithotripsy. J Endourol 1990;4:229-233.
5. Chitale SV, Scott-Barrett S, Ho ET, et al. The management of ureteric obstruction secondary to malignant pelvic disease. Clin Radiol 2002;57:1118-1121.
6. Harding JR. Percutaneous antegrade ureteric stent insertion in malignant disease. J R Soc Med 1993;86:511-513.
7. Jenkins CN, Marcus AJ. The value of antegrade stenting for lower ureteric obstruction. J R Soc Med 1995;88:446-449.
8. McFarlane JP, Cowan C, Holt SJ, et al. Outpatient ureteric procedures: a new method for retrograde ureteropyelography and ueteric stent placement. Br J Urol Int 2001;87:172-176.
9. Yossepowitch O, Lifshitz DA, Dekel Y, et al. Predicting the success of retrograde stent for managing ureteral obstruction. J Urol 2001;166:1746-1749.
10. Carrafiello G, Lagana D, Lumia D, et al. Direct primary or secondary percutaneous ureteral stenting: what is the most compliant options in patients with malignant ureteral obstructions? Cardiovasc Intervent Radiol 2007;30:974-980.
11. Barbaric ZL, Gothlin JH, Davies RS. Transluminal dilatation and stent placement in obstructed ureters in dogs through the use of percutaneous nephropyelostomy. Invest Radiol 1977;6:534-536.
12. Hubert KC, Palmer JS. Passive dilation by ureteral stenting before ureteroscopy: eliminating the need for active dilation. J Urol 2005;174:1079-1080.
13. Weisse C, Berent A. Interventional radiology in urinary diseases. In: Bonagura JD, Twedt DC, eds. Current veterinary therapy XIV. 14th ed. St Louis: Saunders Elsevier, 2008;965-971.
14. Rosevear HM, Kim SP, Wenzler DL, et al. Retrograde ureteral stents for extrinsic ureteral obstruction: nine years' experience at University of Michigan. J Urol 2007;70:846-850.
15. Hao P, Weibing LI, Song C, et al. Clinical evaluation of doublepigtail stent in patients with upper urinary tract diseases: report of 2685 cases. J Endurol 2008;22:65-70.
16. Wong LM, Cleeve LK, Milner AD, et al. Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol 2007;178:178-183.
17. Ku JH, Lee SW, Jeon HG, et al. Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences? J Urol 2004;64:895-899.
18. Norris AM, Laing EJ, Valli VEO, et al. Canine bladder and urethral tumors: a retrospective study of 115 cases (1980-1985). J Vet Intern Med 1992;16:145-153.
19. Knapp DW, Glickman NW, DeNicola DB, et al. Naturally occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer. Urol Oncol 2000;5:47-59.
20. Weisse C, Berent A, Todd K, et al. Evaluation of palliative stenting for management of malignant urethral obstructions in dogs. J Am Vet Med Assoc 2006;229:226-234.
21. Wen JG, Frokiaer J, Jorgensen TM, et al. Obstructive nephropathy: an update of the experimental research. Urol Res 1999;27:29-39.
22. Coroneos E, Assouad M, Krishnan B, et al. Urinary obstruction causes irreversible renal failure by inducing chronic tubulointerstitial nephritis. Clin Nephrol 1997;48:125-128.
23. Wilson DR. Renal function during and following obstruction. Ann Rev Med 1977;28:329-339.
24. Fink RW, Caradis DT, Chmiel R, et al. Renal impairment and its reversibility following variable periods of complete ureteric obstruction. Aust N Z J Surg 1980;50:77-83.
25. Kerr WS. Effect of complete ureteral obstruction for one week on kidney function. J Appl Physiol 1954;6:762-772.
26. Vaughan DE, Sweet RE, Gillenwater JY. Unilateral ureteral occlusion: pattern of nephron repair and compensatory response. J Urol 1973;109:979-982.
27. Hausegger KA, Portugaller HR. Percutaneous nephrostomy and antegrade ureteral stenting: technique-indications-complications. Eur Radiol 2006;16:2016-2030.
28. Knapp DW, Richardson RC, Chan TCK, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
29. Lingeman JE, Preminger GM, Goldfischer ER, et al. Assessing the impact of ureteral stent design on patient comfort. J Urol 2009;181:2581-2587.
30. Vega Vega A, Garcia Alonso D, Garcia Alonso CJ. Characterization of urinary tract symptoms and quality of life in patients with double-pig tailed ureteral stents. Actas Urol Esp 2007;31:738-742.
31. Joshi HB, Stainthorpe A, MacDonagh RP, et al. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 2003;169:1065-1069.
32. Henry CJ, Dudley ML, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder cancer. Clin Can Res 2003;9:906-911.
33. Rocha TA, Mauldin GN, Patnaik AK. Prognostic factors in dogs with urinary bladder carcinoma. J Vet Intern Med 2000;14:486-490.
34. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;112:279-283.
35. Poirier VJ, Forrest LJ, Adams WM, et al. Piroxicam, mitoxantrone and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs. J Am Anim Hosp Assoc 2004;40:131-136.